Zealand Pharma A/S - ADR Financials

$17.59

$0.00 (0.00%)

As on 02-Nov-2022 09:30EDT

Market cap

$814 Mln

Revenue (TTM)

$176 Mln

P/E Ratio

--

P/B Ratio

9.5

Div. Yield

0 %

Annual
Quarterly

Income Statement (Kr. Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	175.50	292.57	353.31	41.33	37.98	139.78
Cost of Revenue	55.42	118.81	90.57	0.42	180.24	14.63
Gross Profit	120.08	173.75	262.75	40.92	-142.26	125.15
Operating Expenses	844.87	1,223.95	1,091.51	628.86	515.59	371.53
Operating Profit (EBIT)	-803.55	-1,052.37	-792.36	-587.94	652.39	-246.38
Other Income	--	--	--	--	--	--
Profit before Tax	-650.53	-1,026.94	-839.65	-576.68	625.06	-277.77
Provision for Tax	10.01	-8.79	7.08	-5.14	43.77	-5.50
Profit after Tax (Net Income)	-701.99	-1,018.15	-846.73	-571.54	581.28	-272.27
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-1,190.49	-1,018.15	-846.73	-571.54	581.28	-274.41

Liabilities (Kr. Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	--	927.80	1,177.09	1,242.67	1,116.28	528.47
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	--	805.51	169.79	161.71	--	132.99
Current Liabilities	261.58	334.32	577.73	195.13	113.52	75.78
Total Liabilities	261.58	2,067.63	1,924.61	1,599.51	1,229.80	737.24

Assets (Kr. Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	--	346.03	679.58	172.46	50.97	34.05
Current Assets	1,000.73	1,721.60	1,245.03	1,427.05	1,178.82	703.19
Total Assets	1,000.73	2,067.63	1,924.61	1,599.51	1,229.80	737.24
Total Debt*	--	787.43	119.85	85.76	--	135.73
Net Current Assets	--	1,387.28	667.30	1,231.92	1,065.31	627.41

Cashflow (Kr. Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-1,211.97	-688.72	-409.46	-460.40	-278.75
Cash Flow from Investing Activities	--	-18.12	-196.81	-51.67	882.93	221.35
Cash from Financing Activities	--	1,332.75	760.94	674.48	-155.45	337.93
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS (Kr.)	--	-23.68	-22.28	-16.81	18.75	-9.72
Cash EPS (Kr.)	--	-22.74	-21.16	-16.41	18.90	-9.55
Adjusted Book Value (Kr.)	--	21.58	30.98	36.55	36.01	18.87
Dividend per Share (Kr.)	--	--	--	--	--	--
Cash Flow per Share (Kr.)	--	-28.19	-18.12	-12.04	-14.85	-9.96
Free Cash Flow per Share (Kr.)	--	-28.70	-18.78	-12.73	-14.98	-10.21

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-67.60	-64.50	-46.76	65.29	-42.72
ROE (%)	--	-96.74	-69.98	-48.46	70.68	-67.51
ROA (%)	-42.54	-51.01	-48.05	-40.40	59.10	-38.03
EBIT Margin (%)	-549.20	-349.61	-236.83	-1,387.44	1,685.59	-185.20
Net Margin (%)	-400.00	-348.01	-239.65	-1,382.77	1,530.62	-194.79
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	-30.37	-0.17	7.55	0.09	-0.73	-0.40
EBIT Growth (%)	16.03	-22.24	-45.91	-189.59	347.29	-103.42
Net Profit Growth (%)	38.86	-20.24	-48.15	-198.32	313.49	-76.90
EPS Growth (%)	--	-0.06	-0.33	-1.90	2.93	--
Book Value Growth (%)	--	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	--	0.85	0.10	0.07	--	0.26
Short term debt to equity ratio	--	0.02	0.01	0.01	--	0.01
Current Ratio	3.83	5.15	2.16	7.31	10.38	9.28
Quick Ratio	3.82	4.80	2.08	7.31	10.38	9.28
Interest Coverage	-26.58	-250.02	-289.04	-178.93	42.45	-13.69

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	47.14	37.73	3.59	38.19	20.64	22.97
Asset Turnover	0.11	0.15	0.20	0.03	0.04	0.20
Receivable days	--	76.83	14.72	104.38	192.10	71.21
Inventory Days	--	252.29	92.15	--	--	--
Payable days	--	190.39	235.61	39,686.83	62.90	613.79
Cash Conversion Cycle	--	138.73	-128.73	-39,582.45	129.20	-542.58

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.